Placeholder Banner

BIO Welcomes Support of Vice President Biden in Fight to Cure Cancer

January 12, 2016

Washington, D.C. (January 12, 2016) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood released the following statement today regarding Vice President Joe Biden’s “moon shot” initiative to find a cure for cancer.

“We applaud Vice President Biden for his leadership in advancing the fight to cure cancer. The process of discovering new cures and treatments for patients in need relies upon an ecosystem of innovation in which all stakeholders, including government agencies and regulators, academic research institutions, private industry, and patient groups, play a critical role.

“America’s innovative biopharmaceutical companies stand ready to work with the Vice President to bring about the day when no cancer patient is faced with a virtual death sentence. Our industry has a long track record of finding breakthrough treatments to once-deadly diseases, including HIV/AIDS, Hepatitis C and an ever-increasing list of cancers. Scientific advancements in the field of medicine have never been as promising as they are today, and we look forward to playing our part in bringing them to patients in need.”

Upcoming BIO Events 

BIO International Convention
June 6-9, 2016
San Francisco, Calif.

BIO CEO & Investor Conference
February 8-9, 2016
New York, New York

13th Annual BIO Asia International Conference
March 15-16, 2016
Tokyo, Japan

BIO-Europe Spring
April 4-6, 2016
Stockholm, Sweden


Discover More
Representatives John Joyce, M.D. (R-PA) and Wiley Nickel (D-NC) today introduced the Optimizing Research Progress Hope And New Cures (ORPHAN Cures Act). BIO President and CEO, Rachel King, made the following remarks: "This legislation is a welcome…
The Biotechnology Innovation Organization has honored two biotechnology leaders who are driving cutting-edge breakthroughs in agricultural, environmental and industrial biotechnology. Dr. Pam Marrone, Co-founder and Executive Chair of Invasive…
Yesterday the Federal Trade Commission (FTC) announced the decision to settle its Amgen-Horizon merger challenge. The settlement will give the Commission the relief it needs to protect competition, while allowing rare disease patients to enjoy the…